CA2274055A1 - Derives du n-piperazine-1-ylphenyl-benzamide - Google Patents

Derives du n-piperazine-1-ylphenyl-benzamide Download PDF

Info

Publication number
CA2274055A1
CA2274055A1 CA002274055A CA2274055A CA2274055A1 CA 2274055 A1 CA2274055 A1 CA 2274055A1 CA 002274055 A CA002274055 A CA 002274055A CA 2274055 A CA2274055 A CA 2274055A CA 2274055 A1 CA2274055 A1 CA 2274055A1
Authority
CA
Canada
Prior art keywords
phenyl
methoxy
6alkyl
methylpiperazin
6alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002274055A
Other languages
English (en)
Inventor
Steven Mark Bromidge
Francis David King
Paul Adrian Wyman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626376.9A external-priority patent/GB9626376D0/en
Priority claimed from GBGB9700902.1A external-priority patent/GB9700902D0/en
Application filed by Individual filed Critical Individual
Publication of CA2274055A1 publication Critical patent/CA2274055A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Cette invention concerne de nouveaux dérivés de carboxamide ayant une activité sur le système nerveux central (SNC), des procédés de préparation de ces nouveaux composés ainsi que leur utilisation en tant que médicaments.
CA002274055A 1996-12-19 1997-12-15 Derives du n-piperazine-1-ylphenyl-benzamide Abandoned CA2274055A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9626376.9A GB9626376D0 (en) 1996-12-19 1996-12-19 Novel compounds
GB9626376.9 1996-12-19
GB9700902.1 1997-01-17
GBGB9700902.1A GB9700902D0 (en) 1997-01-17 1997-01-17 Novel compounds
PCT/EP1997/007160 WO1998027058A2 (fr) 1996-12-19 1997-12-15 Nouveaux composes

Publications (1)

Publication Number Publication Date
CA2274055A1 true CA2274055A1 (fr) 1998-06-25

Family

ID=26310680

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002274055A Abandoned CA2274055A1 (fr) 1996-12-19 1997-12-15 Derives du n-piperazine-1-ylphenyl-benzamide

Country Status (4)

Country Link
EP (1) EP0946551A2 (fr)
JP (1) JP2001506995A (fr)
CA (1) CA2274055A1 (fr)
WO (1) WO1998027058A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2288172A1 (fr) * 1997-04-18 1998-10-29 Smithkline Beecham P.L.C. Aryl bicyclique ou noyau heterocyclique bicyclique contenant des composes presentant une activite antagoniste combinee contre les recepteurs 5ht1a, 5ht1b et 5ht1d
US6316450B1 (en) * 1997-07-11 2001-11-13 Smithkline Beecham P.L.C. Compounds
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
CA2340952C (fr) * 1998-09-10 2009-12-08 F. Hoffmann-La Roche Ag Dihydrobenzodioxine carboxamide et derives de cetone utilises comme antagonistes du recepteur 5-ht4
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
TR200200795T2 (tr) 1999-09-25 2002-07-22 Smithkline Beecham P. L. C. 5-HT1B antagonistleri olarak piperazin türevleri
CN1289072C (zh) 2000-12-22 2006-12-13 石原产业株式会社 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂
BR0206512A (pt) 2001-01-16 2004-01-06 Astrazeneca Ab Composto, método de tratamento de um ser humano ou animal que sofre de depressão, ansiedade generalizada, distúrbios da alimentação, demência, distúrbio do p nico, distúrbios do sono, distúrbios gastrointestinais, distúrbios motores, distúrbios endócrinos, vasoespasmo e disfunção sexual, uso de um composto, e, processo para preparar um composto.
IL156602A0 (en) 2001-01-16 2004-01-04 Astrazeneca Ab Therapeutic chromone compounds
GB0106586D0 (en) * 2001-03-16 2001-05-09 Smithkline Beecham Plc Novel compounds
SE0103644D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
CA2794153C (fr) 2010-03-25 2018-01-02 Glaxosmithkline Llc Derives d'indoline substitue comme inhibiteurs de perk

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119920D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
FR2693201B1 (fr) * 1992-07-01 1994-08-19 Inst Nat Sante Rech Med Nouveaux polypeptides ayant une activité de récepteur sérotoninergique, acides nucléiques codant pour ces polyptides et utilisations.
FR2699533A1 (fr) * 1992-12-21 1994-06-24 Mouhtaram Mohamed Dérivés de N-((1,4-dialkyl-6-arylpipérazine-2-yl)méthyl)benzamides. (Isomères cis et trans) Propriétés pharmacologiques et applications.
GB2273930A (en) * 1992-12-30 1994-07-06 Glaxo Group Ltd Benzanilide derivatives
TW240217B (fr) * 1992-12-30 1995-02-11 Glaxo Group Ltd
DK0689536T3 (da) * 1993-03-16 2001-07-30 Pfizer Naphthalenderivater
GB2276165A (en) * 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benzanilide compounds.
GB2276164A (en) * 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benzanilide derivatives
EP0712397B1 (fr) * 1993-08-06 1999-04-21 Smithkline Beecham Plc Derives amides employes comme antagonistes du recepteur 5ht1d
JPH09503773A (ja) * 1993-10-19 1997-04-15 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ−１ｄレセプター拮抗剤用のベンズアニリド誘導体
EP0661266A1 (fr) * 1993-12-27 1995-07-05 Toa Eiyo Ltd. Composés cycliques aminés substitués comme 5HT2 antagonistes
JPH09507846A (ja) * 1993-12-30 1997-08-12 スミスクライン・ビーチャム・コーポレイション フェニルメチルヘキサンアミドおよびその使用

Also Published As

Publication number Publication date
WO1998027058A3 (fr) 1998-08-20
WO1998027058A2 (fr) 1998-06-25
EP0946551A2 (fr) 1999-10-06
JP2001506995A (ja) 2001-05-29

Similar Documents

Publication Publication Date Title
EP0946539B1 (fr) Derives de sulfamide, procede de preparation de ces derives et utilisation de ces derniers en tant que medicaments
US7439245B2 (en) Compounds
ES2243044T3 (es) Derivados de sulfonamida para el tratamiento de trastornos del snc.
CA2595607A1 (fr) Composes d'arylamine substitues et leur utilisation comme modulateurs de 5-ht6
EP0994862A2 (fr) Nouveaux composes
CA2274055A1 (fr) Derives du n-piperazine-1-ylphenyl-benzamide
US20010051719A1 (en) Novel compounds
US7271168B2 (en) Piperazine derivatives having SST1 antagonistic activity
US6300499B1 (en) α1-adrenergic receptor antagonists
US3872124A (en) N-{8 4-(Phenyl)-piperazino{9 alkyl-thiazole-5-carboxamides
KR20020025179A (ko) 인돌 유도체
US5338735A (en) Pharmaceutical compounds
MXPA99005900A (en) Sulphonamide derivatives, process for their preparation, and their use as medicaments
KR20010112231A (ko) ５―ｈｔ 재흡수 저해제 및 ５―ｈｔ１ｂ／１ｄ리간드로서의 아미드 및 우레아 유도체

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead